vs
Side-by-side financial comparison of COLLEGIUM PHARMACEUTICAL, INC (COLL) and KFORCE INC (KFRC). Click either name above to swap in a different company.
KFORCE INC is the larger business by last-quarter revenue ($330.4M vs $205.4M, roughly 1.6× COLLEGIUM PHARMACEUTICAL, INC). COLLEGIUM PHARMACEUTICAL, INC runs the higher net margin — 8.3% vs 2.4%, a 5.9% gap on every dollar of revenue. On growth, COLLEGIUM PHARMACEUTICAL, INC posted the faster year-over-year revenue change (12.9% vs 0.1%). COLLEGIUM PHARMACEUTICAL, INC produced more free cash flow last quarter ($122.4M vs $-7.4M). Over the past eight quarters, COLLEGIUM PHARMACEUTICAL, INC's revenue compounded faster (19.1% CAGR vs -3.7%).
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical firm focused on developing and commercializing innovative, abuse-deterrent pain management therapies. Operating primarily in the U.S. market, it offers extended-release analgesics for chronic pain patients, serving providers across primary and specialty care segments.
Kforce Inc. is a professional staffing and solutions firm headquartered in the United States. It provides skilled professional placements and specialized workforce solutions primarily across technology, finance & accounting, and healthcare segments, serving a wide range of mid-sized to large enterprise clients nationwide.
COLL vs KFRC — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $205.4M | $330.4M |
| Net Profit | $17.0M | $7.9M |
| Gross Margin | 62.5% | 27.3% |
| Operating Margin | 29.6% | 3.6% |
| Net Margin | 8.3% | 2.4% |
| Revenue YoY | 12.9% | 0.1% |
| Net Profit YoY | 35.3% | -2.7% |
| EPS (diluted) | $0.48 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $330.4M | ||
| Q4 25 | $205.4M | $332.0M | ||
| Q3 25 | $209.4M | $332.6M | ||
| Q2 25 | $188.0M | $334.3M | ||
| Q1 25 | $177.8M | $330.0M | ||
| Q4 24 | $181.9M | $343.8M | ||
| Q3 24 | $159.3M | $353.3M | ||
| Q2 24 | $145.3M | $356.3M |
| Q1 26 | — | $7.9M | ||
| Q4 25 | $17.0M | $5.2M | ||
| Q3 25 | $31.5M | $11.1M | ||
| Q2 25 | $12.0M | $10.4M | ||
| Q1 25 | $2.4M | $8.1M | ||
| Q4 24 | $12.5M | $11.1M | ||
| Q3 24 | $9.3M | $14.2M | ||
| Q2 24 | $19.6M | $14.2M |
| Q1 26 | — | 27.3% | ||
| Q4 25 | 62.5% | 27.2% | ||
| Q3 25 | 61.7% | 27.7% | ||
| Q2 25 | 57.7% | 27.1% | ||
| Q1 25 | 54.8% | 26.7% | ||
| Q4 24 | 54.0% | 27.0% | ||
| Q3 24 | 60.8% | 27.9% | ||
| Q2 24 | 62.5% | 27.8% |
| Q1 26 | — | 3.6% | ||
| Q4 25 | 29.6% | 2.6% | ||
| Q3 25 | 29.7% | 4.5% | ||
| Q2 25 | 18.7% | 4.5% | ||
| Q1 25 | 12.2% | 3.5% | ||
| Q4 24 | 20.9% | 4.5% | ||
| Q3 24 | 21.9% | 5.3% | ||
| Q2 24 | 32.7% | 5.5% |
| Q1 26 | — | 2.4% | ||
| Q4 25 | 8.3% | 1.6% | ||
| Q3 25 | 15.0% | 3.3% | ||
| Q2 25 | 6.4% | 3.1% | ||
| Q1 25 | 1.4% | 2.5% | ||
| Q4 24 | 6.9% | 3.2% | ||
| Q3 24 | 5.9% | 4.0% | ||
| Q2 24 | 13.5% | 4.0% |
| Q1 26 | — | $0.46 | ||
| Q4 25 | $0.48 | $0.29 | ||
| Q3 25 | $0.84 | $0.63 | ||
| Q2 25 | $0.34 | $0.59 | ||
| Q1 25 | $0.07 | $0.45 | ||
| Q4 24 | $0.36 | $0.60 | ||
| Q3 24 | $0.27 | $0.75 | ||
| Q2 24 | $0.52 | $0.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $386.7M | $1.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $301.7M | $117.4M |
| Total Assets | $1.7B | $384.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $1.3M | ||
| Q4 25 | $386.7M | $2.1M | ||
| Q3 25 | $285.9M | $1.3M | ||
| Q2 25 | $222.2M | $2.5M | ||
| Q1 25 | $197.8M | $444.0K | ||
| Q4 24 | $162.8M | $349.0K | ||
| Q3 24 | $120.0M | $127.0K | ||
| Q2 24 | $271.6M | $110.0K |
| Q1 26 | — | $117.4M | ||
| Q4 25 | $301.7M | $124.6M | ||
| Q3 25 | $274.8M | $132.1M | ||
| Q2 25 | $232.2M | $134.4M | ||
| Q1 25 | $234.4M | $138.0M | ||
| Q4 24 | $228.8M | $154.6M | ||
| Q3 24 | $234.3M | $167.4M | ||
| Q2 24 | $216.6M | $166.6M |
| Q1 26 | — | $384.8M | ||
| Q4 25 | $1.7B | $365.6M | ||
| Q3 25 | $1.6B | $374.2M | ||
| Q2 25 | $1.6B | $373.6M | ||
| Q1 25 | $1.6B | $368.2M | ||
| Q4 24 | $1.7B | $357.8M | ||
| Q3 24 | $1.6B | $369.9M | ||
| Q2 24 | $1.1B | $362.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $123.0M | — |
| Free Cash FlowOCF − Capex | $122.4M | $-7.4M |
| FCF MarginFCF / Revenue | 59.6% | -2.2% |
| Capex IntensityCapex / Revenue | 0.3% | 1.0% |
| Cash ConversionOCF / Net Profit | 7.25× | — |
| TTM Free Cash FlowTrailing 4 quarters | $327.6M | $43.3M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $123.0M | $19.7M | ||
| Q3 25 | $78.4M | $23.3M | ||
| Q2 25 | $72.4M | $18.4M | ||
| Q1 25 | $55.4M | $249.0K | ||
| Q4 24 | $84.6M | $21.8M | ||
| Q3 24 | $-9.0M | $31.0M | ||
| Q2 24 | $67.4M | $20.9M |
| Q1 26 | — | $-7.4M | ||
| Q4 25 | $122.4M | $16.7M | ||
| Q3 25 | $78.3M | $19.8M | ||
| Q2 25 | $72.4M | $14.2M | ||
| Q1 25 | $54.6M | $-3.9M | ||
| Q4 24 | $84.1M | $20.9M | ||
| Q3 24 | $-9.2M | $27.5M | ||
| Q2 24 | $67.1M | $17.8M |
| Q1 26 | — | -2.2% | ||
| Q4 25 | 59.6% | 5.0% | ||
| Q3 25 | 37.4% | 6.0% | ||
| Q2 25 | 38.5% | 4.3% | ||
| Q1 25 | 30.7% | -1.2% | ||
| Q4 24 | 46.2% | 6.1% | ||
| Q3 24 | -5.8% | 7.8% | ||
| Q2 24 | 46.2% | 5.0% |
| Q1 26 | — | 1.0% | ||
| Q4 25 | 0.3% | 0.9% | ||
| Q3 25 | 0.1% | 1.1% | ||
| Q2 25 | 0.0% | 1.2% | ||
| Q1 25 | 0.4% | 1.3% | ||
| Q4 24 | 0.3% | 0.3% | ||
| Q3 24 | 0.2% | 1.0% | ||
| Q2 24 | 0.2% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | 7.25× | 3.82× | ||
| Q3 25 | 2.49× | 2.11× | ||
| Q2 25 | 6.05× | 1.76× | ||
| Q1 25 | 22.92× | 0.03× | ||
| Q4 24 | 6.75× | 1.97× | ||
| Q3 24 | -0.96× | 2.18× | ||
| Q2 24 | 3.44× | 1.48× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
